Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.

@article{Mori2013BeneficialRO,
  title={Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.},
  author={Takefumi Mori and Ikuko Oba and Kenji Koizumi and Mayumi Kodama and Miwako Shimanuki and Mizuho Tanno and Makiko Chida and Mai Saito and Hideyasu Kiyomoto and Mariko Miyazaki and Susumu Ogawa and Hiroshi Sato and Sadayoshi Ito},
  journal={Advances in peritoneal dialysis. Conference on Peritoneal Dialysis},
  year={2013},
  volume={29},
  pages={33-7}
}
The V2 receptor antagonist tolvaptan has been approved for volume control in heart-failure patients in Japan. Tolvaptan increases renal blood flow, and so the present study was designed to ascertain whether tolvaptan could be a useful diuretic for volume control without reducing residual renal function (RRF) in peritoneal dialysis (PD) patients. Tolvaptan… CONTINUE READING